BridgeBio Pharma, Inc. (BBIO) vs Madrigal Pharmaceuticals, Inc. (MDGL)
BridgeBio Pharma, Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. is the larger, with a market value of $13.1B against $11.9B — 1.1× the size. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 149.0%. Madrigal Pharmaceuticals, Inc. has the higher net margin (−25.3% vs −97.0%) and the lower return on invested capital (−787.3% vs 0.00%). Across the 16 metrics below, Madrigal Pharmaceuticals, Inc. leads on 10 and BridgeBio Pharma, Inc. on 6.
Valuation
Profitability
| Metric | BBIO | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.44% | 91.48% | 65.16% |
| Operating margin | (69.81%) | (25.13%) | 0.00% |
| Net margin | (97.03%) | (25.32%) | 0.00% |
| Free cash flow margin | (61.06%) | (16.07%) | 0.00% |
| Return on equity | 32.31% | (53.31%) | (57.72%) |
| Return on assets | (60.23%) | (28.77%) | (49.22%) |
| Return on invested capital | 0.00% | (787.33%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack